NASDAQ$ATRA
Atara Biotherapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Atara reported positive data from its pivotal Phase 3 ALLELE study, progress in regulatory submissions for Tab-cel, and durable clinical improvements with ATA188 in progressive multiple sclerosis.
Atara Biotherapeutics reported financial results for the third quarter of 2021, highlighting positive data from the Phase 3 ALLELE study for Tab-cel and progress with ATA188 for multiple sclerosis. The company is preparing for regulatory submissions and continues to advance its CAR T programs.
- Positive data from the pivotal Phase 3 ALLELE study reinforces the transformative potential of Tab-cel.
- Significant regulatory progress for Tab-cel with an imminent EU MAA submission and clarity on FDA requirements for BLA submission planned for Q2 2022.
- ATA188 data demonstrates durable, clinically meaningful disability improvement and possible remyelination in patients with progressive multiple sclerosis.
- Atara is making good progress and expects to submit an IND for ATA3219, an off-the-shelf, allogeneic CD19 CAR T immunotherapy targeting B-cell malignancies, in Q1 2022.
Headline financials
Revenue & EPS history
Atara · Revenue · Quarterly
$5.37M
Forward guidance
Atara believes that its cash as of September 30, 2021, together with the $45.0 million upfront payment received as a result of our entry into the Pierre Fabre Commercialization Agreement, is sufficient to fund planned operations into the second quarter of 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-2.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.1%
Avg return
30 days after
37%
17 / 46 earnings
Positive
+36.3%
Q2 2022
Best reaction
-24.2%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +11.5% | +9.6% | +17.2% | |
| Q4 2025 | -0.6% | -16.4% | -10.7% | |
| Q3 2025 | -1.3% | +4.3% | +43.3% | |
| Q1 2025 | +4.8% | +6.8% | +6.3% | |
| Q4 2024 | +3.9% | -9.2% | +10.6% | |
| Q3 2024 | +21.2% | +2.0% | -7.0% | |
| Q2 2024 | +5.8% | -7.5% | +9.6% | |
| Q1 2024 | -6.3% | +6.9% | -6.5% | |
| Q4 2023 | +3.6% | +4.0% | -1.4% | |
| Q3 2023 | -7.8% | +2.3% | -49.8% | |
| Q2 2023 | -16.4% | -7.1% | -31.6% | |
| Q1 2023 | -16.2% | -26.5% | -43.3% | |
| Q4 2022 | -12.6% | -18.7% | -48.2% | |
| Q3 2022 | -18.0% | +8.5% | +0.2% | |
| Q2 2022 | +36.3% | +69.8% | +32.3% | |
| Q1 2022 | -5.3% | -22.2% | -29.7% | |
| Q4 2021 | -22.6% | -32.9% | -30.4% | |
| Q3 2021 | -3.1% | -4.4% | -8.9% | |
| Q2 2021 | +0.8% | -1.5% | +17.9% | |
| Q1 2021 | -3.9% | -3.3% | -5.1% | |
| Q4 2020 | +1.0% | -4.2% | -14.4% | |
| Q3 2020 | -5.9% | +9.0% | +72.0% | |
| Q2 2020 | +1.9% | +3.5% | +4.8% | |
| Q1 2020 | +4.9% | +17.5% | +11.7% | |
| Q4 2019 | +8.8% | +11.5% | -24.4% | |
| Q3 2019 | +10.2% | +6.9% | +15.0% | |
| Q2 2019 | +10.6% | +17.3% | +16.4% | |
| Q1 2019 | -24.2% | -27.1% | -35.6% | |
| Q4 2018 | -13.3% | -8.5% | -7.4% | |
| Q3 2018 | -1.9% | -3.5% | +5.7% | |
| Q2 2018 | -2.1% | +0.5% | +9.1% | |
| Q1 2018 | -5.8% | +1.7% | +0.6% | |
| Q4 2017 | -10.6% | -8.6% | -9.5% | |
| Q3 2017 | -6.3% | -4.9% | +3.1% | |
| Q2 2017 | -3.3% | -3.6% | -1.3% | |
| Q1 2017 | -5.1% | -7.0% | -10.2% | |
| Q4 2016 | +21.4% | +16.8% | -1.2% | |
| Q3 2016 | +17.2% | +45.6% | +32.6% | |
| Q2 2016 | -9.5% | -14.7% | -14.3% | |
| Q1 2016 | -5.5% | — | — | |
| Q4 2015 | -18.5% | — | — | |
| Q3 2015 | +4.7% | — | — | |
| Q2 2015 | -11.4% | — | — | |
| Q1 2015 | -1.7% | — | — | |
| Q4 2014 | -5.9% | — | — | |
| Q3 2014 | -15.5% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro